Hoch Allison I, Mittal Vaishali, Mitra Debika, Vollmer Nina, Zikry Christopher A, Leach J Kent
Department of Biomedical Engineering, University of California, Davis, Davis, CA 95616, United States.
Department of Biomedical Engineering, University of California, Davis, Davis, CA 95616, United States; Department of Orthopaedic Surgery, School of Medicine, University of California, Davis, Sacramento, CA 95817, United States.
Biomaterials. 2016 Jan;74:178-87. doi: 10.1016/j.biomaterials.2015.10.003. Epub 2015 Oct 9.
Prior to transplantation, mesenchymal stem/stromal cells (MSCs) can be induced toward the osteoblastic phenotype using a cocktail of soluble supplements. However, there is little evidence of differentiated MSCs directly participating in bone formation, suggesting that MSCs may either die or revert in phenotype upon transplantation. Cell-secreted decellularized extracellular matrices (DMs) are a promising platform to confer bioactivity and direct cell fate through the presentation of a complex and physiologically relevant milieu. Therefore, we examined the capacity of biomimetic DMs to preserve the mineral-producing phenotype upon withdrawal of the induction stimulus. Regardless of induction duration, ranging up to 6 weeks, MSCs exhibited up to a 5-fold reduction in osteogenic markers within 24 h following stimulus withdrawal. We show that seeding osteogenically induced MSCs on DMs yields up to 2-fold more calcium deposition than tissue culture plastic, and this improvement is at least partially mediated by increasing actin cytoskeletal tension via the ROCK II pathway. MSCs on DMs also secreted 25% more vascular endothelial growth factor (VEGF), a crucial endogenous proangiogenic factor that is abrogated during MSC osteogenic differentiation. The deployment of DMs into a subcutaneous ectopic site enhanced the persistence of MSCs 5-fold, vessel density 3-fold, and bone formation 2-fold more than MSCs delivered without DMs. These results underscore the need for deploying MSCs using biomaterial platforms such as DMs to preserve the in vitro-acquired mineral-producing phenotype and accelerate the process of bone repair.
在移植前,间充质干/基质细胞(MSCs)可以使用可溶性补充剂混合物诱导成骨细胞表型。然而,几乎没有证据表明分化的MSCs直接参与骨形成,这表明MSCs在移植后可能死亡或表型逆转。细胞分泌的脱细胞细胞外基质(DMs)是一个很有前景的平台,通过呈现复杂且生理相关的环境来赋予生物活性并指导细胞命运。因此,我们研究了仿生DMs在撤除诱导刺激后保持产矿表型的能力。无论诱导持续时间长达6周,MSCs在撤除刺激后24小时内成骨标志物最多降低5倍。我们发现,将成骨诱导的MSCs接种在DMs上比接种在组织培养塑料上产生的钙沉积多2倍,这种改善至少部分是通过ROCK II途径增加肌动蛋白细胞骨架张力来介导的。接种在DMs上的MSCs还多分泌25%的血管内皮生长因子(VEGF),这是一种关键的内源性促血管生成因子,在MSC成骨分化过程中被消除。将DMs植入皮下异位部位比未使用DMs递送的MSCs使MSCs的持久性提高5倍、血管密度提高3倍、骨形成提高2倍。这些结果强调了使用DMs等生物材料平台来递送MSCs以保持体外获得的产矿表型并加速骨修复过程的必要性。